HLA-DRα Antibody (B-10): sc-55592

HLA-DRα Antibody (B-10) is a mouse monoclonal IgG1 antibody that detects HLA-DRα in mouse, rat, and human samples through various applications including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and enzyme-linked immunosorbent assay (ELISA). HLA-DRα is a crucial component of the major histocompatibility complex (MHC) class II molecules, which play a vital role in the immune response by presenting processed antigens to CD4+ T helper cells. HLA-DRα (B-10) antibody enables research into adaptive immune system activation, as HLA-DRα facilitates the recognition of foreign peptides, thereby influencing T cell activation and differentiation. HLA-DRα is primarily located on the surface of antigen-presenting cells, such as B cells and dendritic cells, where HLA-DRα forms heterodimers with HLA-DRβ chains. This localization allows for effective presentation of antigens to T cells, which is critical for initiating immune responses. Additionally, HLA-DRα undergoes various post-translational modifications, including glycosylation, which can affect stability, expression levels, and interaction with other proteins, ultimately influencing the immune response. Anti-HLA-DRα antibody (B-10) serves as an invaluable tool for researchers studying immune mechanisms, autoimmune diseases, and the role of MHC class II molecules in health and disease.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

HLA-DRα Antibody (B-10) References:

1. An ATF/CREB binding motif is required for aberrant constitutive expression of the MHC class II DR alpha promoter and activation by SV40 T-antigen.  |  Cox, PM. and Goding, CR. 1992. Nucleic Acids Res. 20: 4881-7. PMID: 1329030
2. The HLA-DRalpha chain is modified by polyubiquitination.  |  Lapaque, N., et al. 2009. J Biol Chem. 284: 7007-16. PMID: 19117940
3. A new monoclonal antibody recognizing a linear determinant on the HLA-DRalpha chain N-terminus.  |  Ting, YT., et al. 2009. Hybridoma (Larchmt). 28: 423-9. PMID: 20025501
4. [Molecular cloning and three-dimensional structure modelling of HLA-DRalpha * 0101, DRbeta1 * 04051 and DRbeta1 * 07011].  |  Sun, YY., et al. 2001. Zhongguo Ying Yong Sheng Li Xue Za Zhi. 17: 281-4. PMID: 21189634
5. Molecular cytogenetic analysis of human breast tumors: methylation pattern of the HLA-DRα gene.  |  Barbieri, R., et al. 1987. Cytotechnology. 1: 83-5. PMID: 22358447
6. Major Histocompatibility Complex Class II HLA-DRα Is Downregulated by Kaposi's Sarcoma-Associated Herpesvirus-Encoded Lytic Transactivator RTA and MARCH8.  |  Sun, Z., et al. 2016. J Virol. 90: 8047-58. PMID: 27356905
7. Significance of incorporation of DNMT1 and HLA-DRα with TNM staging in patients with hepatocellular carcinoma after curative resection.  |  Tang, H., et al. 2017. Int J Clin Exp Pathol. 10: 9372-9381. PMID: 31966809
8. The HLA-DQ(alpha 1*0102, beta 1*0602) heterodimer may confer susceptibility to multiple sclerosis in the absence of the HLA-DR(alpha 1*01, beta 1*1501) heterodimer.  |  Spurkland, A., et al. 1997. Tissue Antigens. 50: 15-22. PMID: 9243750
9. Novel glycosylation of HLA-DRalpha disrupts antigen presentation without altering endosomal localization.  |  Guerra, CB., et al. 1998. J Immunol. 160: 4289-97. PMID: 9574531
10. Regulation of HLA-DR and costimulatory B7 molecules in human thyroid carcinoma cells: differential binding of transcription factors to the HLA-DRalpha promoter.  |  Lahat, N., et al. 1998. Thyroid. 8: 361-9. PMID: 9623725

The preferred HLA-DRα antibody is HLA-DRα Antibody (G-7): sc-55593.